Literature DB >> 33679769

Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.

Judith Derdelinckx1,2, Patrick Cras2,3, Zwi N Berneman1,4, Nathalie Cools1,4.   

Abstract

Antigen-specific therapy for multiple sclerosis may lead to a more effective therapy by induction of tolerance to a wide range of myelin-derived antigens without hampering the normal surveillance and effector function of the immune system. Numerous attempts to restore tolerance toward myelin-derived antigens have been made over the past decades, both in animal models of multiple sclerosis and in clinical trials for multiple sclerosis patients. In this review, we will give an overview of the current approaches for antigen-specific therapy that are in clinical development for multiple sclerosis as well provide an insight into the challenges for future antigen-specific treatment strategies for multiple sclerosis.
Copyright © 2021 Derdelinckx, Cras, Berneman and Cools.

Entities:  

Keywords:  antigen-specific therapy; experimental autoimmune encephalomyelitis; multiple sclerosis; myelin; tolerance induction

Year:  2021        PMID: 33679769      PMCID: PMC7933447          DOI: 10.3389/fimmu.2021.624685

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  125 in total

Review 1.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

2.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

Authors:  H L Weiner; G A Mackin; M Matsui; E J Orav; S J Khoury; D M Dawson; D A Hafler
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

3.  T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients.

Authors:  A Achiron; G Lavie; I Kishner; Y Stern; I Sarova-Pinhas; T Ben-Aharon; Y Barak; H Raz; M Lavie; T Barliya; M Faibel; I R Cohen; M Mandel
Journal:  Clin Immunol       Date:  2004-11       Impact factor: 3.969

Review 4.  Epicutaneous and Oral Low-Zone Tolerance Protects from Colitis in Mice.

Authors:  Talkea Schmidt; Nadine Lorenz; Verena Raker; Sonja Reißig; Ari Waisman; Benno Weigmann; Kerstin Steinbrink
Journal:  J Invest Dermatol       Date:  2016-05-17       Impact factor: 8.551

5.  Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals.

Authors:  Laureline Berthelot; David-Axel Laplaud; Ségolène Pettré; Caroline Ballet; Laure Michel; Sophie Hillion; Cécile Braudeau; Francine Connan; Fabienne Lefrère; Sandrine Wiertlewski; Jean-Gérard Guillet; Sophie Brouard; Jeannine Choppin; Jean-Paul Soulillou
Journal:  Eur J Immunol       Date:  2008-07       Impact factor: 5.532

6.  T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Authors:  Dimitrios Karussis; Hagai Shor; Julia Yachnin; Naama Lanxner; Merav Amiel; Keren Baruch; Yael Keren-Zur; Ofra Haviv; Massimo Filippi; Panayiota Petrou; Shalom Hajag; Urania Vourka-Karussis; Adi Vaknin-Dembinsky; Salim Khoury; Oded Abramsky; Henri Atlan; Irun R Cohen; Rivka Abulafia-Lapid
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

7.  'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides.

Authors:  Nathali Kaushansky; Nicole Kerlero de Rosbo; Rina Zilkha-Falb; Reut Yosef-Hemo; Lydia Cohen; Avraham Ben-Nun
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

8.  Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis.

Authors:  Geoffrey D Keeler; Sandeep Kumar; Brett Palaschak; Emily L Silverberg; David M Markusic; Noah T Jones; Brad E Hoffman
Journal:  Mol Ther       Date:  2017-09-21       Impact factor: 11.454

9.  Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis.

Authors:  Melanie D Leech; Chen-Yen Chung; Abigail Culshaw; Stephen M Anderton
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

10.  Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.

Authors:  N Karin; D J Mitchell; S Brocke; N Ling; L Steinman
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  2 in total

1.  The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation.

Authors:  Cinzia Volonté; Savina Apolloni; Susanna Amadio
Journal:  Curr Top Behav Neurosci       Date:  2022

2.  Synergistic targeting of immunologic pathways to empower durable tolerance therapies.

Authors:  Gerald T Nepom
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.